[Intraocular injections of bevacizumab in rare indications--two cases].
Intravitreal anti-VEGF injections are currently the most effective treatment option for neovascular age-related macular degeneration. The anti-VEGF treatment of other, more common ocular diseases, such as diabetic retinopathy and vascular occlusions with neovascularization and retinal edema, is currently described in numerous studies and cases. Rare neovascular ocular diseases, such as Eales disease, presumed ocular histoplasmosis syndrome (POHS), retinopathy of prematurity, and idiopathic telangiectasia, may be future areas for anti-VEGF therapy. In our case report we describe intravitreal bevacizumab (Avastin) therapy for central serous chorioretinopathy and for pseudoxanthoma elasticum with angioid streaks and choroidal neovascularization. In both cases the intravitreal injection resulted in morphological and functional rehabilitation.
Wecke
T
T
Universitätsaugenklinik Magdeburg, Leipziger Strasse 44, 39120, Magdeburg. Thoralf.Wecke@Medizin.Uni-Magdeburg.de
Knop
C
C
Schreiber
W
W
Behrens-Baumann
W
W
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007267:Injections; D008875:Middle Aged; D011561:Pseudoxanthoma Elasticum / Q000175:diagnosis / Q000188:drug therapy*; D035583:Rare Diseases / Q000175:diagnosis / Q000188:drug therapy; D012162:Retinal Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab